Hepatotoxicity of contemporary antiretroviral drugs

Christina G. Rivera, Ashley O. Otto, John D. Zeuli, Zelalem Temesgen

Research output: Contribution to journalReview articlepeer-review


Purpose of reviewTo date, more than 30 antiretroviral drugs have been approved by the Food and Drug Administration for the treatment of HIV infection. As new drugs with better efficacy and safety profile become available for clinical practice, older drugs are either withdrawn from the market or become no longer actively prescribed. We review hepatotoxicity associated with contemporary antiretroviral drugs, with emphasis on data from the past 3 years.Recent findingsAlthough less robust data exists for side effects of contemporary antiretroviral medications recently approved for the management of HIV (i.e., doravirine, ibalizumab, fostemsavir, cabotegravir), the risks of substantial hepatotoxicity appears to be minimal with these agents.SummaryAlthough newer antiretroviral drugs are better tolerated than their earlier counterparts, they are not completely devoid of adverse drug reactions, including hepatotoxicity. Monitoring patients on antiretroviral therapy for treatment-emergent liver injury should continue to be part of routine clinical care.

Original languageEnglish (US)
Pages (from-to)279-285
Number of pages7
JournalCurrent Opinion in HIV and AIDS
Issue number6
StatePublished - Nov 1 2021


  • HIV infections
  • anti-HIV agents
  • antiretroviral agents
  • chemical and drug-induced liver injury

ASJC Scopus subject areas

  • Infectious Diseases
  • Oncology(nursing)
  • Hematology
  • Oncology
  • Virology
  • Immunology


Dive into the research topics of 'Hepatotoxicity of contemporary antiretroviral drugs'. Together they form a unique fingerprint.

Cite this